 |
|
Allogeneic Hematopoietic Stem Cell Transplantation
Complications and Results
Imad A. Tabbara, MD;
Kathy Zimmerman, RN;
Connie Morgan;
Zeina Nahleh, MD
Arch Intern Med. 2002;162:1558-1566.
Acute complications such as veno-occlusive disease of the liver, acute and chronic graft-vs-host disease (GVHD), and infectious conditions remain major obstacles for the success of allogeneic hematopoietic stem cell transplantation (HSCT). Progress in allogeneic HSCT depends on several factors, including the adequate prevention and management of associated complications, advances in the conventional management of diseases currently treated with allogeneic HSCT, expansion of the donor pool, selective control of GVHD, development of more effective preparative regimens to eradicate the neoplastic cell population, characterization of a new generation of hematopoietic growth factors and cytokines, and development of newer techniques for ex vivo manipulation of stem cells. Hematopoietic growth factor–mobilized donor progenitor cells collected from peripheral blood have been shown to be associated with rapid hematopoietic engraftment without an increase in the incidence of acute GVHD compared with allogeneic bone marrow transplantation. Implementation of this approach will enhance donor acceptance, eliminate the risk of general anesthesia, decrease cost, and reduce the risk of infectious complications by reducing the duration of neutropenia. Nonmyeloablative allogeneic stem cell transplantation represents a novel treatment approach that may lead to reduced toxic effects and extended use of this treatment in older patients and in those with malignant and nonmalignant disorders. However, GVHD and disease recurrence remain a challenge. Promising results have been reported in patients with refractory hematologic malignancies and in metastatic renal cell cancer. Because late complications are commonly encountered in patients receiving allogeneic HSCT, lifelong observation is needed.
From the Bone Marrow Transplant Program, University of Virginia Health System, Charlottesville (Dr Tabbara and Mss Zimmerman and Morgan); and the George Washington University Medical Center, Washington, DC (Dr Nahleh).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Enlargement of the Common Bile Duct in Patients With Acute Graft-Versus-Host Disease: What Does It Mean?
Ketelsen et al.
Am. J. Roentgenol. 2009;193:W181-W185.
ABSTRACT
| FULL TEXT
Clinical molecular imaging in intestinal graft-versus-host disease: mapping of disease activity, prediction, and monitoring of treatment efficiency by positron emission tomography
Stelljes et al.
Blood 2008;111:2909-2918.
ABSTRACT
| FULL TEXT
CT features of hepatic venoocclusive disease and hepatic graft-versus-host disease in patients after hematopoietic stem cell transplantation.
Erturk et al.
Am. J. Roentgenol. 2006;186:1497-1501.
ABSTRACT
| FULL TEXT
Graft-vs-Host Disease: Nutrition Therapy in a Challenging Condition
Roberts and Thompson
Nutr Clin Pract 2005;20:440-450.
ABSTRACT
| FULL TEXT
Long-Term Health-Related Quality of Life, Growth, and Spiritual Well-Being After Hematopoietic Stem-Cell Transplantation
Andrykowski et al.
JCO 2005;23:599-608.
ABSTRACT
| FULL TEXT
Chimerism of Metanephric Adenoma but Not of Carcinoma in Kidney Transplants
Mengel et al.
Am. J. Pathol. 2004;165:2079-2085.
ABSTRACT
| FULL TEXT
Anti-Thrombin III in the Management of Hematopoietic Stem-Cell Transplantation-Associated Toxicity
Ibrahim et al.
The Annals of Pharmacotherapy 2004;38:1053-1059.
ABSTRACT
| FULL TEXT
CT Features with Pathologic Correlation of Acute Gastrointestinal Graft-Versus-Host Disease After Bone Marrow Transplantation in Adults
Kalantari et al.
Am. J. Roentgenol. 2003;181:1621-1625.
ABSTRACT
| FULL TEXT
Allogeneic Stem Cell Transplantation for Chronic Myeloproliferative Disorders and Myelodysplastic Syndromes: The Question Is 'When?'
Maziarz et al.
Mayo Clin Proc. 2003;78:941-943.
|
